Company intelligence / Profile preview

KinoTeck Therapeutics Co., Ltd

Guangdong Sheng, China

Ownership: Private
Development stage: Other

Overview

KinoTeck Therapeutics is a private Chinese biotech company focused on developing small molecule therapies targeting cancer. Its lead program, KNT-0916, is an FGFR2 inhibitor currently in Phase I clinical trials for FGFR2-altered solid tumors. Another program, BW-710, also targets FGFR2 and is in preclinical development for neoplasms. The company has also disclosed research into RSK-2 and WRN inhibitors as potential cancer therapeutics[1][4][6].

Therapeutic areas: Oncology
Modalities: Small moleculesChemical drugs
Industry: Biotech

Drug pipeline

1 asset

KNT-0916

Beyond the preview

Go deeper on KinoTeck Therapeutics Co., Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KinoTeck Therapeutics Co., Ltd.